Trials / Completed
CompletedNCT03410446
Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine Hydrochloride | Ketamine is a N-methyl-D-aspartate (NMDA) antagonist. |
Timeline
- Start date
- 2018-07-16
- Primary completion
- 2021-11-27
- Completion
- 2021-11-27
- First posted
- 2018-01-25
- Last updated
- 2022-05-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03410446. Inclusion in this directory is not an endorsement.